Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28985524.
- Also identified by DOI 10.1016/j.stem.2017.09.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As genome editing rapidly progresses toward the realization of its clinical promise, assessing the suitability of current tools and processes used for its benefit-risk assessment is critical. Although current regulations may initially provide an adequate regulatory framework, improvements are recommended to overcome several existing technology-based safety and efficacy issues.
Medical subject headings
- Gene Editing
- Genome, Human
- Risk Assessment
- Social Control, Formal